Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs
详细信息 查看全文
- 作者：David Charles ; P. ; Padaliya ; Bimal B. ; Newman ; William J. ; Gill ; Chandler E. ; Covington ; Cassondra D. ; et. al.
- 关键词：Parkinson's disease ; Deep brain stimulation ; Subthalamic nucleus ; Antiparkinsonian medications ; Cost analysis
- 刊名：Parkinsonism and Related Disorders
- 出版年：2004
- 出版时间：December, 2004
- 年：2004
- 卷：10
- 期：8
- 页码：475-479
- 全文大小：164 K
文摘
This study reports a retrospective analysis of 16 patients to determine changes in medication costs associated with deep brain stimulation of the bilateral subthalamic nucleus (DBS B-STN). Antiparkinsonian medication (APMED) costs were evaluated pre- and post-operatively at 1 and 2 years, based on prescribed dosages. After treatment with DBS, patients experienced a 32 % reduction in APMED costs after 1 year and a 39 % reduction after 2 years. Hypothetical projections of total potential savings are presented, accounting for increasingly complex medication regimens and medication cost inflation. DBS patients may experience a significant long-term reduction in the cost of their pharmacologic treatment.